Cereneo, Center For Rehabilitation and Neurology
Vitznau, Canton of Lucerne, 6354, Switzerland
NCT Number: NCT02315963
High motivation is a predictor for good therapy results in physical therapy [Grahn 2000]. The investigator want to show that it is possible to increase patients motivation for stroke rehabilitation by providing them objective performance feedback about the patients therapy progress.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Vitznau, Canton of Lucerne, 6354, Switzerland
High motivation is a predictor for good therapy results in physical therapy [Grahn 2000]. Additional focus on motivation and rewards has fallen on the topic of stroke rehabilitation since it was shown in an animal model that the brain centers involved with motivation and rewards are crucial to motor learning [Hosp 2011].
The investigators goal is to target the overall motivation for therapy. During the guided therapy sessions the therapists will be the main motivators and the investigators do not want to interfere with that. But the amount of guided therapy sessions is often limited due to economical reason rather than therapeutic ones. Therefore patients are encouraged to do training on their own if possible and to be active during the patients stay in the rehabilitation clinic. The investigators target the patients motivation to train by themselves and be active but also the patients attitude towards the guided therapies. It is known that performance feedback can improve motivation [Harackiewicz 1979]. Therefore the investigators want to use the data about therapy progress to produce feedback for patients visualizing the patients progress and efforts during the patients stay in the clinic.
The investigators will compare patients who receive normal therapy to patients who receive normal therapy plus performance feedback regarding a variety of motivation measures.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
Time frame: Weekly for the duration of the participants stay at the hospital an expected average of 6 weeks
Weekly: Intrinsic Motivation Inventory Questionnaire
Time frame: After each therapy session for the duration of the participants stay at the hospital an expected average of 6 weeks
Motivation rating of patients regarding the foregoing therapy session by therapists
Time frame: Continuous for the duration of the participants stay at the hospital an expected average of 6 weeks
Time patient spends on self administered training
Time frame: Continuousfor the duration of the participants stay at the hospital an expected average of 6 weeks
Amount of activities (walking, stair climbing) during free time
Time frame: When decided by therapists for the duration of the participants stay at the hospital an expected average of 6 weeks
Standard quality assessments of the study site (rehabilitation clinic)
Cereneo AG
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details